United States· US:0548-5001_0e71b74d-723d-46a4-b2e5-7c7157949ad4

Ganirelix Acetate

A ganirelix product containing ganirelix acetate, registered in United States by Amphastar Pharmaceuticals, Inc.. The same ATC class is registered in 17 of our 19 countries.

ATC H01CC01US label

Checked against FDA National Drug Code directory (United States) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ganirelix acetateAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ganirelix is registered in 17 of 19 countries.

Countries holding a registration under ATC H01CC01 (ganirelix), each read from that country’s own register.

This record: United States, from FDA National Drug Code directory (United States)
10 of them publish a price we can compare per daily dose

Search ganirelix products by name

Ganirelix · ATC H01CC01

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Spainprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)

Active substance: GANIRELIX ACETATE
Manufacturer: Amphastar Pharmaceuticals, Inc.
Country: United States (US)
ATC code: H01CC01
ATC class: Ganirelix
Defined daily dose: 0.25 mg, P
Reimbursed: Not published by this register
Source register: FDA National Drug Code directory (United States)
Last checked: September 27, 2026

Packs & prices · 2

ndc11
0548-5001-00
ndc11
0548500100
1 SYRINGE in 1 CARTON (0548-5001-00) / .5 mL in 1 SYRINGE

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for ganirelix.

Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ganirelix against other medicines How interaction checks work

Ganirelix · interactions on record

7 records

7 moderate

Most severe, free to view

Chorionic gonadotrophinG03GA01moderate
Menotropin HMGG03GA02moderate
UrofollitropinG03GA04moderate
GonadorelinH01CA01moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ganirelix in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ganirelix products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

Austria · Ganirelix Astro, Ganirelix Theramex
Belgium · Fyremadel, Ovamex
Bulgaria · Ganirelix Theramex
Czechia · Fyremadel
Germany · Fyremadel, Ganiran
Denmark · Fyremadel, Ganirelix Orifarm
Estonia · Ganirelix Theramex
Spain · Astarté, Fyremadel
Finland · Fyremadel, Ganirelix Orifarm
France · Fyremadel, Ganirelix Eg
United Kingdom (Northern Ireland) · Fyremadel
Greece · Fyremadel, Ovamex
Croatia · Ganireliks Theramex
Hungary · Ganirelix Theramex
Iceland · Ganirelix, Ganirelix Gedeon Richter
Italy · Fyremadel, Ovamex
Liechtenstein · Ganirelix, Ganirelix Gedeon Richter
Lithuania · Ganirelix Theramex
Latvia · Ganirelix Theramex
Netherlands · Fyremadel, Ganirelix Fagron
Norway · Fyremadel, Ganirelix
Poland · Fyremadel, Ovamex
Portugal · Astarté, Fyremadel
Sweden · Fyremadel, Ganirelix Orifarm
Slovenia · Ganireliks Theramex
Slovakia · Fyremadel, Ganirelix Theramex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/c30aadd9-9404-4486-bb21-705cac150c60
GET /v1/drugs/c30aadd9-9404-4486-bb21-705cac150c60?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "source": "ndc",
  "strength": "250",
  "substance": "GANIRELIX ACETATE",
  "productndc": "0548-5001",
  "dosage_form": "INJECTION",
  "dea_schedule": null,
  "strength_unit": "ug/.5mL",
  "application_number": "ANDA212613",
  "marketing_category": "ANDA"
}

API reference MCP server Plans

See everything about ganirelix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console